Latest News & Features
Americas
Teva has filed an application with the US Supreme Court to stay a ruling by the US Court of Appeals for the Federal Circuit that allowed generic drug makers to enter the market before the expiry of Teva’s patents covering its $4.3 billion-a-year multiple sclerosis drug Copaxone. 8 April 2014
Americas
OxyContin (oxycodone hydrochloride) maker Purdue Pharma has filed suit against Teva to stop the generic drug maker trying to litigate claims to a patent for which it had filed a Paragraph III certification. 8 April 2014
Asia
Mumbai-based Sun Pharmaceutical Industries is buying Indian rival Ranbaxy Laboratories in a merger worth $3.2 billion, the companies have confirmed. 7 April 2014
Americas
Cooley LLP has recruited Ivor Elrifi and Heidi Erlacher to the patent counselling team serving the life sciences and technology sectors. 3 April 2014
Americas
Generic drug maker Prasco Laboratories has agreed to market and distribute an authorised generic version of Eli Lilly’s Evista (raloxifene hydrochloride) in the US. 3 April 2014
Americas
Schiff Hardin LLP has expanded its IP group with the hiring of Imron Aly as a partner. 2 April 2014
Americas
The US Court of Appeals for the Federal Circuit has reversed a lower court decision that found Actavis’s generic version of Shire’s ulcerative colitis drug Lialda (mesalamine) infringes US patent 6,773,720. 2 April 2014
Americas
The US Supreme Court has agreed to hear Teva’s appeal against a Federal Circuit decision that invalidated a patent covering its $4.3 billion-a-year Copaxone (glatiramer acetate) drug, allowing Sandoz, Mylan and Natco to produce generic versions. 1 April 2014
Americas
The US District Court for the Southern District of Indiana has upheld a patent covering Eli Lilly’s second biggest drug Alimta (pemetrexed disodium), after a challenge by Teva’s US pharmaceutical arm. 1 April 2014
article
Many researchers are unaware of the legalities when it comes to sharing and using copyrighted material, but licensing agreements can help, says Kate Alzapiedi of copyright licensing firm RightsDirect. 31 March 2014